Eli Lilly and Company (NYSE:LLY) will present new data across its dermatology portfolio at the 2026 Fall Clinical Dermatology Conference taking place Oct. 8-11 in Las Vegas. Twenty-one poster presentations provide insights spanning disease control, treatment experience and outcomes across patient populations, demonstrating Lilly's commitment to addressing the everyday burden of chronic dermatologic diseases such as atopic dermatitis, psoriasis and alopecia areata. Key data presentations include EBGLYSS (lebrikizumab-lbkz) for the treatment of moderate-to-severe atopic dermatitis and the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) in psoriasis and obesity or overweight.